PT -期刊文章盟-马丁·j·布罗迪盟帕维尔•克莱恩AU -拉曼Sankar盟-巴里·e·Gidal盟Dwain托尔博特TI - IV卡马西平的连续性护理:维持治疗的病例报告(P5.235) DP - 2017年4月18日TA -神经病学PG - P5.235 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P5.235.short 4100 - http://n.neu首页rology.org/content/88/16_Supplement/P5.235.full所以Neurology2017 4月18日;88 AB -目的:描述一个病例报告说明了维护卡马西平治疗的重要性。背景:批准在1970年代中期以来,口服卡马西平已广泛应用在很多年前开始治疗的患者,它仍然是一个负担得起的选择对病人从较低的社会经济团体和/或那些高额的保险计划。尽管卡马西平是一种已知的细胞色素P450 (CYP)同功酶的诱导物,开处方者可能不知道在撤军毒性的风险。下情况下口服卡马西平是暂时行不通,连续性静脉卡马西平的护理配方(IV-CBZ)将比为了保持de-induction发作控制和避免可能的影响。设计/方法:病例报告的卡马西平(卡马西平)de-induction被描述。结果:51岁女性历史的癫痫、风湿性心脏病、二尖瓣瓣膜,和不受控制的癫痫症状经历1 - 2其次广义发作/月尽管使用苯妥英、卡马西平;病人同时接受地高辛和华法林。苯妥英慢慢收回,病人是维护在拉莫三嗪(150毫克b.i.d。)和卡马西平不断更新的配方(400毫克b.i.d)。三年后,病人有经验的共济失调和被称为全科医生到另一个医院,那时卡马西平几个月前在门诊中撤出。病人死亡后不久进入急诊室休克和严重的背痛。 Cause of death was unrecognized retroperitoneal hemorrhage due to warfarin toxicity secondary to de-induction following CBZ withdrawal.Conclusions: Managing concomitant treatments in CBZ-treated patients can be difficult as altering a stable dosage of CBZ can affect exposure to other medications. The use of IV-CBZ can maintain patients’ stable CBZ treatment when oral administration is impracticable, avoiding untoward and potentially dangerous side effects of CBZ de-induction.Study Supported by: Lundbeck LLCDisclosure: Dr. Brodie has received personal compensation for activities with UCB Pharma, Eisai Ltd, Lundbeck Inc., GW Pharmaceuticals, Bial, GlaxoSmithKline, Sanofi Aventis, and Abbot for grants/research support, honoraria, consulting fees, or speakers bureau. Dr. Klein has received personal compensation for activities with Eisai, Sunovion, and UCB Inc. as a speaker. Dr. Klein has received personal compensation for activities with Lundbeck LLC, Sunovion, and UCB Inc. as an advisory board member. Dr. Klein has received research support from Eisai and Lundbeck LLC. Dr. Sankar has received personal compensation for activities with Lundbeck, Eisai, UCB Pharma, Supernus, Sunovion, Upsher-Smith, and Cyberonics. Dr. Gidal has received personal compensation for activities with UCB, Eisai, and Sunovion for speaking engagements. Dr. Gidal has received personal compensation from UCB, Eisai, Sunovion, Upsher-Smith, Lundbeck LLC, and SK-Bioscience as a consultant. Dr. Tolbert has received personal compensation for activities with Lundbeck LLC.